AtriCure, Inc. 10-Q Summary: Quarter Ended March 31, 2010
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2010. AtriCure, Inc. is a medical device company developing, manufacturing, and selling devices for the surgical ablation of cardiac tissue, primarily to treat atrial fibrillation (AF). The company operates as a single reporting segment with sales in the United States and internationally. As of April 30, 2010, there were 15,461,019 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2010 | Q1 2009 |
|---|---|---|
| Revenues | $13,951,800 | $13,673,903 |
| Gross Profit | $10,679,164 | $10,729,245 |
| Gross Margin | 76.5% | 78.5% |
| Net Loss | $(2,009,351) | $(7,964,922) |
| Loss Per Share (Basic/Diluted) | $(0.13) | $(0.56) |
| Cash and Cash Equivalents | $3,655,505 | $8,905,425 (Dec 31, 2009) |
| Short-Term Investments | $8,189,204 | $6,816,673 (Dec 31, 2009) |
| Total Debt (Current + Long-Term) | $4,394,321 | $4,897,097 (Dec 31, 2009) |
| Working Capital | $17,878,389 | $19,544,678 (Dec 31, 2009) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 2.0% year-over-year, driven by a 26.9% increase in international sales ($2.9M vs $2.3M), partially offset by a decline in U.S. sales.
- Profitability Improvement: Net loss narrowed significantly to $2.0M from $8.0M in Q1 2009. This improvement is largely due to the absence of a $6.8M goodwill impairment charge recorded in Q1 2009.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased 8.7% to $9.7M due to higher headcount and travel costs. Research and development (R&D) expenses decreased 8.9% to $2.7M.
- Cash Flow: Net cash used in operating activities increased to $3.0M (from $2.4M), primarily due to the net loss, increased accounts receivable, and inventory build-up. Net cash used in investing activities was $1.8M, driven by purchases of available-for-sale securities.
Guidance, Outlook, and Risks
- Regulatory Developments:
- DEEP AF Trial: Conditionally approved by the FDA on May 7, 2010, to evaluate minimally invasive products for persistent AF.
- ABLA Trial: Final PMA filing is no longer expected in the first half of 2010 due to ongoing FDA discussions.
- AtriClip System: FDA clearance is now anticipated in the first half of 2011, as the FDA may request additional animal testing.
- Isolator Synergy: The FDA indicated a 510(k) filing was required for cardiac tissue ablation indications. AtriCure submitted this on April 26, 2010, and voluntarily re-labeled products to reflect soft tissue ablation.
- Legal and Compliance:
- DOJ Settlement: Finalized in February 2010 regarding False Claims Act investigations. Total liability is approximately $4.35M (including interest), with $3.5M remaining as of March 31, 2010. The company entered a five-year Corporate Integrity Agreement.
- Class Action: A securities class action lawsuit remains pending; the company recorded a $2.0M reserve and a corresponding insurance receivable.
- Healthcare Reform: The Patient Protection and Affordable Care Act imposes a 2.3% excise tax on medical device sales, which will increase expenses and potentially reduce revenues.
- Liquidity: Management believes current cash, investments, and credit facility availability ($1.7M) are sufficient for operations for at least the next 12 months.
Investor Verification Checklist
- Verify the status and timeline of the 510(k) submission for the Isolator Synergy system and potential impact on current sales.
- Monitor the DOJ settlement payments and compliance requirements under the Corporate Integrity Agreement.
- Assess the impact of the 2.3% medical device excise tax on future gross margins.
- Review the credit facility covenants with Silicon Valley Bank, noting the recent waiver of a compliance violation in February 2010.
- Track the progress of the DEEP AF clinical trial and the revised timeline for the AtriClip system clearance.